Results 151 to 160 of about 7,834 (208)

DCMiC: a double-cylinder micro-chamber platform for high-throughput drug screening and modeling of microenvironmental resistance in Ewing sarcoma. [PDF]

Lab Chip
Lee J, Ye M, Ybarra M, Fei J, Gao Y, Ma C.   +5 more
europepmc   +1 more source

Emerging Therapeutic Synergies: Combining PD-1 Inhibitors With Poly-ADP-Ribose Polymerase (PARP) Inhibitors in the Treatment of Gynecologic Cancers. [PDF]

Cureus
Mohamed Azhar MS, Loh Z, Mutamba FT, Algahiny A, Yunusa NM, Paramasevon S, Almusarhed M.   +6 more
europepmc   +1 more source

Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study. [PDF]

Ther Adv Med Oncol
Peng X, Song R, Fan Y, Wang J, Li Q, Mo H, Wang J, Luo Y, Chen S, Sun X, Zhang J, Zhang P, Xu B, Lan B, Ma F.   +14 more
europepmc   +1 more source

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes. [PDF]

Invest New Drugs
Autio KA, Kyriakopoulos CE, Palyca P, Xiao H, Emamekhoo H, Danila D, Jan M, Catharine V, Riedel E, Devitt M, Laird AD, Scher HI.   +11 more
europepmc   +1 more source

Computational Chemistry Advances in the Development of PARP1 Inhibitors for Breast Cancer Therapy. [PDF]

Pharmaceuticals (Basel)
Twala C, Govender P, Govender K.
europepmc   +1 more source

Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma. [PDF]

J Cell Mol Med
Stoof J, Andrieu C, O'Connell F, O'Sullivan J, Lowery MA, Walsh N.   +5 more
europepmc   +1 more source

The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose. [PDF]

FEBS Lett
Bashtanova U, Duer MJ.
europepmc   +1 more source

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. [PDF]

Proc Natl Acad Sci U S A
Traphagen NA, Wheeler E, Li R, Akhshi T, Ravindranathan R, Alfieri C, Lu F, Ahmed B, Tewari AK, Balk SP, Nelson PS, Corey E, Long H, D'Andrea AD, Qiu X, Brown M.   +15 more
europepmc   +1 more source

Roles of ADP-Ribosyltransferases in Cancer. [PDF]

Oncol Res
Veilleux M, Nguyen A, Cao C, Shi Y.
europepmc   +1 more source

Characteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors: A Single-Institution Experience. [PDF]

Cancers (Basel)
Akkoc Mustafayev FN, Fountzilas E, Munsell MF, Layman RM, Yam C, Gutierrez AM, Albarracin CT, Ahmed Z, Schlacher K, Tainer JA, Arun BK.   +10 more
europepmc   +1 more source